Candidiasis Market to Surpass US$ 1,307.2 Million by 2026 | Astellas Pharma Inc., Grupo Ferrer Internacional, S.A., Pacgen Life Science Corporation

Increasing adoption of inorganic growth strategies such as mergers and acquisitions for the development of novel drugs by market players is expected to propel the market growth. For instance, in March 2018, NovaQuest Capital Management L.L.C. acquired Viamet Pharmaceuticals (NC), Inc., which included the company's product candidate, VT-1161, which successfully completed Phase 2b clinical trials. The product is indicated for the treatment of recurrent vulvovaginal candidiasis and onychomycosis (fungal nail infection). Moreover, in 2014, NovaDigm Therapeutics acquired the rights to three Candida vaccine antigens from the Los Angeles BioMedical Research Institute at Harbor-UCLA Medical Center, which significantly strengthened the company's candida vaccine pipeline.

Request a sample report @ https://www.coherentmarketinsights.com/insight/request-sample/229

The market is expected to register significant growth as various research institutes are focused on developing novel drug combinations to enhance drug efficacy. For instance, in June 2019, microbiologists at the Beth Israel Deaconess Medical Center (BIDMC) demonstrated that combination of anti-fungal and anti-bacterial medications can effectively target multidrug resistant Candida auris. Similarly in October 2018, researchers at the American Society for Microbiology identified a compound alexidine dihydrochloride, which has the highest antifungal and anti-biofilm activity against a diverse range of fungal pathogens, thus having a greater potential for use as a pan-antifungal drug.

Key Players

Major players operating in the global candidiasis market include, Basilea Pharmaceutica Ltd., Astellas Pharma Inc., Grupo Ferrer Internacional, S.A., Pacgen Life Science Corporation, NovaDigm Therapeutics, Inc., Cidara Therapeutics, Inc., Amplyx Pharmaceuticals Inc., and Pfizer, Inc.

Key Developments

Major institutes and universities are focused on R&D activities related to candidiasis. For instance, on September 09, 2019, a team of researchers from Southmead Hospital, Bristol, in collaboration with Triticum Exploitatie B.V., tested the vulnerability of Candida albicans to honey and an MGH formulation (L-Mesitran) by evaluating five isolates from vaginal samples of symptomatic patients suffering from recurrent vulvovaginal candidiasis.

In August 2019, researchers from Complutense University of Madrid developed fast-dissolving orodispersible films of amphotericin B for oropharyngeal candidiasis.

Download PDF brochure of this report @ https://www.coherentmarketinsights.com/insight/request-pdf/229

In July 2019, researchers from Instituto de Química Rosario, Argentina, designed chitosan nanoformulations for the delivery of antifungal agents. The approach can aid in the development of a pharmaceutical dosage form suitable for the treatment of vaginal candidiasis.

Coherent Market Insights 1001 4th Ave,
#3200 Seattle, WA 98154,U.S.
Phone: US +1-206-701-6702/UK +44-020 8133 4027
Email: sales@coherentmarketinsights.com

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. Our client base includes players from across all business verticals in over 150 countries worldwide. We are uniquely positioned to help businesses around the globe deliver practical and lasting results through various recommendations about operational improvements, technologies, emerging market trends and new working methods.

This release was published on openPR.